Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities
pharmaceutical investing Helix BioPharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody From the Government of Canada
Helix BioPharma Announces the Signing of a Non-Binding Letter of Intent With ProMab Biotechnologies to Develop Cell Based Therapies
Helix BioPharma Corp. Announces L-DOS47 Immuno-Oncology Scientific Presentation at the Medical University of Warsaw
EnerCom Announces Initial List of Presenting Companies for the 31st Annual Energy Investment Conference to be held August 17-19, 2026, in Denver, Colorado
